Square Pharmaceuticals PLC. (DSE: SQURPHARMA)
Bangladesh
· Delayed Price · Currency is BDT 222.80
+0.20 (0.09%)
At close: Dec 19, 2024
DSE: SQURPHARMA Cash Flow Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2019 - 2015 |
| Net Income | 21,017 | 20,926 | 18,980 | 18,157 | 15,947 | 13,354 | Upgrade
|
| Depreciation & Amortization | 2,279 | 2,319 | 2,310 | 1,835 | 1,882 | 1,921 | Upgrade
|
| Other Amortization | - | - | - | - | - | 49.49 | Upgrade
|
| Loss (Gain) From Sale of Assets | 203.85 | 208 | 79.8 | -53.49 | -34.43 | - | Upgrade
|
| Loss (Gain) From Sale of Investments | - | - | - | - | -177.04 | - | Upgrade
|
| Loss (Gain) on Equity Investments | -2,781 | -2,572 | -2,523 | -2,011 | -1,291 | - | Upgrade
|
| Other Operating Activities | -5,735 | -5,268 | -4,654 | -3,838 | -3,330 | -3,698 | Upgrade
|
| Change in Accounts Receivable | 137.08 | 869.7 | -1,262 | -522.93 | -115.84 | 41.52 | Upgrade
|
| Change in Inventory | -2,694 | -354.95 | -4,177 | -968.71 | -1,558 | -1,091 | Upgrade
|
| Change in Accounts Payable | 441.93 | 428.94 | 375.77 | -40.18 | 127.76 | -163.2 | Upgrade
|
| Change in Income Taxes | 150.48 | 556.17 | -555.41 | 338.83 | -405.36 | - | Upgrade
|
| Change in Other Net Operating Assets | 497.16 | 1,417 | -29.96 | -22.88 | -69.56 | 347.24 | Upgrade
|
| Operating Cash Flow | 13,518 | 18,529 | 8,546 | 12,875 | 10,976 | 10,760 | Upgrade
|
| Operating Cash Flow Growth | 14.55% | 116.82% | -33.62% | 17.29% | 2.01% | -13.17% | Upgrade
|
| Capital Expenditures | -5,413 | -4,181 | -2,861 | -6,183 | -3,798 | -2,042 | Upgrade
|
| Sale of Property, Plant & Equipment | 107.3 | 97.44 | 78.33 | 130.7 | 80.13 | 60.74 | Upgrade
|
| Investment in Securities | -7,313 | -7,221 | -858.01 | -1,416 | -798.2 | -2,413 | Upgrade
|
| Other Investing Activities | 6,945 | 4,256 | 4,428 | 3,499 | 3,239 | 2,939 | Upgrade
|
| Investing Cash Flow | -5,673 | -7,049 | 787.69 | -3,970 | 3,607 | -1,866 | Upgrade
|
| Long-Term Debt Issued | - | - | 72.7 | 1,811 | 103.71 | - | Upgrade
|
| Total Debt Issued | - | - | 72.7 | 1,811 | 103.71 | - | Upgrade
|
| Long-Term Debt Repaid | - | -557.89 | - | - | - | - | Upgrade
|
| Total Debt Repaid | -420.71 | -557.89 | - | - | - | - | Upgrade
|
| Net Debt Issued (Repaid) | -420.71 | -557.89 | 72.7 | 1,811 | 103.71 | - | Upgrade
|
| Issuance of Common Stock | - | - | - | - | 0.5 | - | Upgrade
|
| Common Dividends Paid | -9,233 | -9,237 | -8,803 | -5,302 | -3,923 | -3,314 | Upgrade
|
| Other Financing Activities | -37.7 | -37.7 | -32.23 | -262.5 | - | - | Upgrade
|
| Financing Cash Flow | -9,692 | -9,833 | -8,762 | -3,754 | -3,819 | -3,314 | Upgrade
|
| Foreign Exchange Rate Adjustments | 384.37 | 271.89 | 560.97 | 447.1 | 35.61 | -20.05 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | - | - | - | - | -0 | - | Upgrade
|
| Net Cash Flow | -1,463 | 1,919 | 1,132 | 5,598 | 10,800 | 5,560 | Upgrade
|
| Free Cash Flow | 8,105 | 14,348 | 5,685 | 6,692 | 7,178 | 8,718 | Upgrade
|
| Free Cash Flow Growth | -15.75% | 152.37% | -15.04% | -6.78% | -17.66% | -15.71% | Upgrade
|
| Free Cash Flow Margin | 11.57% | 20.47% | 9.36% | 11.62% | 14.16% | 19.00% | Upgrade
|
| Free Cash Flow Per Share | 9.14 | 16.19 | 6.41 | 7.55 | 8.10 | 9.83 | Upgrade
|
| Cash Interest Paid | 218.26 | 246.14 | 87.68 | 0.03 | 0.01 | 0.11 | Upgrade
|
| Cash Income Tax Paid | 4,409 | 4,320 | 5,127 | 4,494 | 4,595 | 3,831 | Upgrade
|
| Levered Free Cash Flow | 5,640 | 11,603 | 2,948 | 4,800 | 10,672 | 5,455 | Upgrade
|
| Unlevered Free Cash Flow | 5,809 | 11,755 | 3,022 | 4,800 | 10,672 | 5,455 | Upgrade
|
| Change in Net Working Capital | 1,890 | -2,258 | 6,859 | 1,390 | -3,045 | 3,142 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.